The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
Researchers will use Adaptive's immune repertoire sequencing technology to look for a molecular signature of type 1 diabetes.
Scripps Research Translational Institute has teamed with Nvidia to create a center of excellence for AI in genomics and wearable sensors.
Stanford University's Michael Snyder found that methylome shifts preceded spikes in his blood glucose levels, suggesting profiling could detect disease.
DefiniGen said it plans to use ERS Genomics' technology to create disease models to support drug discovery for type 2 diabetes and other conditions.
DefiniGen said it plans to use the Broad's technology to create disease models to support the development of therapeutics for metabolic diseases.
Each stage is associated with an increase in gut microbial diversity and is influenced by breastfeeding, researchers reported this week.
The phenome-wide association study focused on SNPs near potential drug target sites with ties to one or more phenotypes that might impact target suitability.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.